Promore Pharma has recruited half of the patients in HEAL LL-37
STOCKHOLM, 20 June 2019 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that half of the patients have been enrolled and started the treatment in the company’s Phase II-study (HEAL) with the company’s product candidate LL-37 for treatment of venous leg ulcers. With the same pace in recruitment all patients should be included and randomized in the beginning of 2020.Promore Pharma’s phase IIb study with LL-37, HEAL (A Study in Patients with Hard-to-Heal Venous Leg Ulcers to Measure Efficacy and Safety of Locally Administered LL-37) is